Global clinical studies on skin regeneration have demonstrated that a single treatment with MA-ECM significantly stimulates wound healing by accelerating the re-epithelialization of chronic wound sites. MA-ECM, derived from the patient’s own (autologous) adipose tissue, contains a rich composition of hundreds of essential proteins, growth factors, and cytokines that play a crucial role in the wound-healing process.
Beyond autologous therapy, ROKIT Healthcare’s disruptive 3D bioprinting technology delivers personalized, regenerative solutions for treating refractory diabetic foot ulcers and chronic wounds. This breakthrough approach offers a potent and transformative alternative for patients suffering from non-healing wounds, providing them with an improved quality of life and enhanced healing potential.